Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lyell Immunopharma, Inc. - Common Stock (NQ:LYEL)

17.51 -0.37 (-2.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lyell Immunopharma, Inc. - Common Stock

< Previous 1 2 Next >
Lyell Immunopharma Announces Participation in March Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing
Six presentations highlight innovations designed to shorten TIL manufacturing, new nonclinical data on LYL119, new technologies and clinical trials in progress 
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Presentations to highlight new nonclinical data on product candidates, new technologies, innovations designed to shorten TIL manufacturing and clinical trials in progress 
From Lyell Immunopharma, Inc
Via GlobeNewswire
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
From Lyell Immunopharma, Inc; Cellares
Via GlobeNewswire
Lyell Immunopharma to Participate in Upcoming Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma to Participate in BofA Securities Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma to Participate in BofA Securities Biotech Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma to Participate in Credit Suisse Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer
From Lyell Immunopharma, Inc
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.